Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

Puntos clave

• To determine if combining ixekizumab with tirzepatide provides better disease control in adults with psoriatic arthritis and obesity.
• Randomized trial comparing ixekizumab plus tirzepatide vs. ixekizumab alone
• Population included adults with psoriatic arthritis and overweight or obesity
• Significant improvement in disease control was observed with ixekizumab plus tirzepatide compared to ixekizumab alone.